A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 08 Nov 2018 According to a Daiichi Sankyo Company media release, data from this trial was presented at the 2018 European Society for Medical Oncology (ESMO) Congress.
- 31 Aug 2018 Biomarkers information updated
- 07 Mar 2018 According to a Daiichi Sankyo Company media release, the first part of the study is expected to enroll approximately 50 patients, following the outcome of the first part of the study two additional exploratory cohorts may proceed to enroll patients whose tumors have lower levels of HER2-expression.